In vivo behavior of monocytes in resting and inflammatory conditions
单核细胞在静息和炎症条件下的体内行为
基本信息
- 批准号:8370505
- 负责人:
- 金额:$ 40.82万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-11-15 至 2015-10-31
- 项目状态:已结题
- 来源:
- 关键词:Angiotensin IIAngiotensin II ReceptorAngiotensin-Converting Enzyme InhibitorsAnimal ModelBehaviorBehavioralBiologicalBiologyBloodBone MarrowCellsCessation of lifeDataDendritic CellsDiseaseDistantEducationFDA approvedFigs - dietaryFluorescenceHealedHomeostasisImageImmunityImmunologyInflammationInflammatoryInjuryLaboratoriesLeukocytesLocationMaintenanceMeasuresMolecularMusMyocardial InfarctionOrganPathway interactionsPeripheralPlayPopulationRecruitment ActivityRelative (related person)ResearchResolutionResourcesRestRoleSignal TransductionSiteSpleenSplenic Red PulpSystemSystems BiologyTechnologyTestingTherapeuticTimeTissuesTouch sensationUndifferentiatedWorkbasecell motilitycellular imaginghealingin vivoinjuredmacrophagemonocytenovelnovel therapeutic interventionnovel therapeuticsperipheral bloodpreventpublic health relevanceresearch studyresponse
项目摘要
DESCRIPTION (provided by applicant): Protection of injured or infected tissue involves the coordinated delivery of migratory leukocytes. Thus, current research efforts aim to define the mechanisms that control the movement of these cells into and out of specific tissues. Here, we will study monocytes because these cells play a central role in the orchestration and resolution of tissue inflammation, and thus represent attractive targets in therapy. Monocytes recruited to tissue are thought to originate exclusively from blood and bone marrow. However, recent work indicates that the spleen contains bona fide, undifferentiated monocytes that outnumber their blood equivalents. Also, splenic monocytes can be mobilized massively to inflammatory sites upon appropriate stimulation. These findings form the basis of our hypothesis that the spleen is a site for storage and rapid deployment of monocytes, and that splenic monocytes represent a significant resource that the body exploits to control inflammation. At present, there is a need to clarify the spleen-associated mechanisms that control monocyte homeostasis and function. In a first aim, we will measure parameters that define the biology of monocytes in the resting spleen (cell turnover, education vs maintenance, location and organization, and in vivo behavior). These studies are necessary to uncover fundamental aspects of monocyte behavior and the role of the spleen as a monocyte storage organ. In a second aim, we will define mechanisms that are employed to mobilize splenic monocytes. We will study AT-1 receptor-Angiotensin II (Ang II) signaling because it is a newly identified pathway that controls mobilization of spM. We will define the spM response to Ang II signals, and study whether modulation of Ang II signaling can be used to control the monocyte response. Our data indicate that suppression of Ang II signaling abolishes the deployment of spM and consequently suppresses the monocyte response at distant sites. Thus, these studies have important therapeutic potential. We will use state-of-the-art animal models and readouts that are available in the laboratory; these include time-lapse intravital cellular imaging to interrogate the behavior of monocytes in vivo, and profiling of 'minimally- touched' cells for comprehensive analysis in distinct tissues. We have developed and/or validated the technology over the past three years, and will now apply it to answer the biological questions relevant to monocytes. Our experiments will compare two monocyte subsets (Ly-6Chi and Ly-6Clo) because they appear to play different roles in immunity, yet their relative contributions need clarification. In vivo imaging will use newly- generated Cx3cr1gfp/+ Ccr2rfp/+ mice because monocyte subsets in these mice can be followed separately. The project will interact closely with local (Weissleder, Luster and Xavier at MGH; von Andrian at HMS) and outside (Charo at UCSF) immunology, imaging and systems biology groups.
描述(由申请人提供):对受伤或感染组织的保护涉及迁移白细胞的协调输送。因此,目前的研究努力旨在确定控制这些细胞进出特定组织的运动机制。在这里,我们将研究单核细胞,因为这些细胞在组织炎症的协调和解决中起着核心作用,因此是治疗中有吸引力的靶点。被组织吸收的单核细胞被认为完全来源于血液和骨髓。然而,最近的研究表明,脾脏含有真正的、未分化的单核细胞,其数量超过血液中的同类细胞。此外,脾单核细胞在适当的刺激下可以被大量动员到炎症部位。这些发现构成了我们假设的基础,即脾脏是单核细胞储存和快速部署的场所,脾脏单核细胞代表了身体控制炎症的重要资源。目前,有必要明确脾脏相关的控制单核细胞稳态和功能的机制。在第一个目标中,我们将测量定义静息脾脏中单核细胞生物学的参数(细胞周转,教育与维持,位置和组织以及体内行为)。这些研究对于揭示单核细胞行为的基本方面和脾脏作为单核细胞储存器官的作用是必要的。在第二个目标中,我们将定义动员脾单核细胞的机制。我们将研究AT-1受体-血管紧张素II (Ang II)信号,因为它是一个新发现的控制spM动员的途径。我们将定义spM对Ang II信号的反应,并研究是否可以通过调节Ang II信号来控制单核细胞的反应。我们的数据表明,抑制Ang II信号可以消除spM的部署,从而抑制远端单核细胞的反应。因此,这些研究具有重要的治疗潜力。我们将使用实验室中可用的最先进的动物模型和读数;这些包括延时活体细胞成像,以询问单核细胞在体内的行为,以及在不同组织中对“最小接触”细胞进行综合分析。在过去的三年中,我们已经开发和/或验证了这项技术,现在将应用它来回答与单核细胞相关的生物学问题。我们的实验将比较两种单核细胞亚群(Ly-6Chi和Ly-6Clo),因为它们似乎在免疫中发挥不同的作用,但它们的相对贡献需要澄清。体内成像将使用新生成的Cx3cr1gfp/+ Ccr2rfp/+小鼠,因为这些小鼠中的单核细胞亚群可以单独跟踪。该项目将与本地(MGH的Weissleder、Luster和Xavier; HMS的von Andrian)和外部(UCSF的Charo)免疫学、成像和系统生物学小组密切合作。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mikael PITTET其他文献
Mikael PITTET的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mikael PITTET', 18)}}的其他基金
Project 3: Myeloid-lymphoid cell crosstalk in HNSCC therapy
项目 3:HNSCC 治疗中的骨髓-淋巴细胞串扰
- 批准号:
10478901 - 财政年份:2019
- 资助金额:
$ 40.82万 - 项目类别:
Project 3: Myeloid-lymphoid cell crosstalk in HNSCC therapy
项目 3:HNSCC 治疗中的骨髓-淋巴细胞串扰
- 批准号:
10251171 - 财政年份:2019
- 资助金额:
$ 40.82万 - 项目类别:
Project 3: Myeloid-lymphoid cell crosstalk in HNSCC therapy
项目 3:HNSCC 治疗中的骨髓-淋巴细胞串扰
- 批准号:
10020927 - 财政年份:2019
- 资助金额:
$ 40.82万 - 项目类别:
Imaging endogenously produced tumor derived micro vesicles
内源性产生的肿瘤衍生微泡的成像
- 批准号:
8974820 - 财政年份:2014
- 资助金额:
$ 40.82万 - 项目类别:
In vivo behavior of monocytes in resting and inflammatory conditions
单核细胞在静息和炎症条件下的体内行为
- 批准号:
8579869 - 财政年份:2010
- 资助金额:
$ 40.82万 - 项目类别:
In vivo behavior of monocytes in resting and inflammatory conditions
单核细胞在静息和炎症条件下的体内行为
- 批准号:
8077662 - 财政年份:2010
- 资助金额:
$ 40.82万 - 项目类别:
In vivo behavior of monocytes in resting and inflammatory conditions
单核细胞在静息和炎症条件下的体内行为
- 批准号:
8035646 - 财政年份:2010
- 资助金额:
$ 40.82万 - 项目类别:
In vivo behavior of monocytes in resting and inflammatory conditions
单核细胞在静息和炎症条件下的体内行为
- 批准号:
9416059 - 财政年份:2010
- 资助金额:
$ 40.82万 - 项目类别:
In vivo behavior of monocytes in resting and inflammatory conditions
单核细胞在静息和炎症条件下的体内行为
- 批准号:
8765711 - 财政年份:2010
- 资助金额:
$ 40.82万 - 项目类别:
In vivo behavior of monocytes in resting and inflammatory conditions
单核细胞在静息和炎症条件下的体内行为
- 批准号:
8196963 - 财政年份:2010
- 资助金额:
$ 40.82万 - 项目类别:
相似海外基金
Early endothelial function activation by angiotensin II receptor blockers prevents vascular damage in a model of diabetes
血管紧张素 II 受体阻滞剂早期激活内皮功能可预防糖尿病模型中的血管损伤
- 批准号:
493141 - 财政年份:2023
- 资助金额:
$ 40.82万 - 项目类别:
Clinical benefits and mechanism of action of angiotensin-II receptor blocker on Cardiovascular remodeling in patients with repaired coarctation of aorta
血管紧张素II受体阻滞剂对主动脉缩窄修复患者心血管重塑的临床疗效及作用机制
- 批准号:
10734120 - 财政年份:2023
- 资助金额:
$ 40.82万 - 项目类别:
Targeting cancer-associated fibroblasts and tumour hypoxia with angiotensin II receptor blockers
使用血管紧张素 II 受体阻滞剂靶向癌症相关成纤维细胞和肿瘤缺氧
- 批准号:
445961 - 财政年份:2021
- 资助金额:
$ 40.82万 - 项目类别:
Operating Grants
Antitumor effect of HCC and exosome microRNA by angiotensin II receptor blockers and molecular target drugs
血管紧张素II受体阻滞剂和分子靶向药物对HCC和外泌体microRNA的抗肿瘤作用
- 批准号:
19K17401 - 财政年份:2019
- 资助金额:
$ 40.82万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Pleiotropic activation of endothelial function by angiotensin II receptor blockers is crucial to their protective anti-vascular remodeling effects
血管紧张素 II 受体阻滞剂对内皮功能的多效性激活对其保护性抗血管重塑作用至关重要
- 批准号:
411570 - 财政年份:2019
- 资助金额:
$ 40.82万 - 项目类别:
Heterogeneity of Angiotensin II Receptor Blockers in the inhibition of Marfan-associated Aortic Root Dilation Independent of Blood Pressure Effects
血管紧张素 II 受体阻滞剂抑制马凡相关主动脉根部扩张的异质性,与血压影响无关
- 批准号:
391615 - 财政年份:2018
- 资助金额:
$ 40.82万 - 项目类别:
Relationship between serum EETs concentrations and cardiovascular events in patients taking angiotensin II receptor blockers
服用血管紧张素II受体阻滞剂的患者血清EETs浓度与心血管事件的关系
- 批准号:
26460229 - 财政年份:2014
- 资助金额:
$ 40.82万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The development of new angiotensin II receptor vaccine
新型血管紧张素II受体疫苗的研制
- 批准号:
25870715 - 财政年份:2013
- 资助金额:
$ 40.82万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Central GRK5 modulation of Angiotensin II receptor expression in heart failure
GRK5 对心力衰竭中血管紧张素 II 受体表达的中枢调节
- 批准号:
8531707 - 财政年份:2012
- 资助金额:
$ 40.82万 - 项目类别:
Central GRK5 modulation of Angiotensin II receptor expression in heart failure
GRK5 对心力衰竭中血管紧张素 II 受体表达的中枢调节
- 批准号:
8397394 - 财政年份:2012
- 资助金额:
$ 40.82万 - 项目类别: